Literature DB >> 9818729

Thymulin stimulates prolactin and thyrotropin release in an age-related manner.

O A Brown1, Y E Sosa, F Bolognani, R G Goya.   

Abstract

Thymulin is a Zn-bound nonapeptide produced by the thymic epithelial cells (TEC) whose secretion is modulated by prolactin (PRL) and thyroid hormones, among other hormones. We assessed the ability of thymulin to influence the release of PRL and thyroid stimulating hormone (TSH) from dispersed anterior pituitary (AP) cells from young, middle-aged and senescent Sprague-Dawley female rats. Perifused and incubated AP cells were used in different sets of experiments and PRL and TSH release was measured by radioimmunoassay. Perifusion of young and senescent AP cells with thymulin doses ranging from 10(-8) to 10(-5) M gave a logarithmic dose response pattern for both hormones. Supernatants from TEC lines also showed PRL and TSH secretagogue activity. Hormone release was always lower in the senescent cells. AP cells incubated with 10(-8) to 10(-3) M thymulin showed a time- and dose-dependent response for both hormones, the latter being bell-shaped with a maximum at 10(-7) M thymulin. Preincubation of thymulin with an anti-thymulin serum completely quenched the secretagogue activity of the thymic hormone. Coincubation of thymulin with TRH revealed a synergistic release of PRL and TSH in AP cells from all age groups. The calcium chelator EGTA but not the calcium ionophore A23187, blocked the hormone-releasing activity of thymulin in AP cells. The cAMP enhancers, caffeine, NaF and forskolin, significantly increased the thymulin-stimulated release of PRL and TSH, while trifluoperazine, a protein kinase C inhibitor, had no effect. The inositol phosphate enhancer LiCl, potentiated the action of thymulin on PRL and TSH. The present results suggest that the TRH-like activity documented here for thymulin is a receptor-mediated effect which appears to involve calcium, cAMP and inositol phosphates. Senescence but not middle age, appears to impair AP cell responsiveness to thymulin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818729     DOI: 10.1016/s0047-6374(98)00072-4

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  5 in total

1.  Thymulin-based gene therapy and pituitary function in animal models of aging.

Authors:  Paula C Reggiani; Brenda Poch; Gloria M Cónsole; Omar J Rimoldi; Jose I Schwerdt; Victoria Tüngler; Margarita M Garcia-Bravo; Mireille Dardenne; Rodolfo G Goya
Journal:  Neuroimmunomodulation       Date:  2011-09-22       Impact factor: 2.492

2.  Neonatal thymulin gene therapy prevents ovarian dysgenesis and attenuates reproductive derangements in nude female mice.

Authors:  Paula C Reggiani; Claudio G Barbeito; Gustavo O Zuccolilli; Gloria M Cónsole; Alicia M Flamini; Mireille Dardenne; Rodolfo G Goya
Journal:  Endocrinology       Date:  2012-06-14       Impact factor: 4.736

3.  Thymulin gene therapy prevents the reduction in circulating gonadotropins induced by thymulin deficiency in mice.

Authors:  Rodolfo G Goya; Paula C Reggiani; Silvan M Vesenbeckh; Jean M Pléau; Yolanda E Sosa; Gloria M Cónsole; Rüdiger Schade; Peter Henklein; Mireille Dardenne
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-03-27       Impact factor: 4.310

4.  Partial prevention of hepatic lipid alterations in nude mice by neonatal thymulin gene therapy.

Authors:  Margarita M García de Bravo; Mónica P Polo; Paula C Reggiani; Omar J Rimoldi; Mireille Dardenne; Rodolfo G Goya
Journal:  Lipids       Date:  2006-08       Impact factor: 1.880

Review 5.  The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin.

Authors:  Paula C Reggiani; Gustavo R Morel; Gloria M Cónsole; Claudio G Barbeito; Silvia S Rodriguez; Oscar A Brown; Maria Jose Bellini; Jean-Marie Pléau; Mireille Dardenne; Rodolfo G Goya
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.